Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

Equity investee earnings-17517480Net income $
33,897(a)$
21,140(c)$
94,732(b)$
32,189(d)Basic earnings per share$
.63(a)$
.35(c)$
.73(b)$
2.22(d)Weighted average shares outstanding - basic53,698,33459,730,27054,844,64159,629,788Diluted earnings per share$
.61(a)$
.35(c)$
.68(b)$
2.16(d)Weighted average shares outstanding - diluted55,197,96861,080,38756,290,01061,091,354(a) Three months ended December 31, 2012 include, as applicable, $10,191 in restructuring costs ($6,968 net of tax), $3,613 favorable inventory adjustment ($2,502 net of tax) and $2,850 in losses at sites that were closed during the period ($1,966 net of tax).(b) Year ended December 31, 2012 includes, as applicable, $33,930 in restructuring costs ($23,145 net of tax), $21,168 in inventory impairment charges and costs associated with the expected settlement of an inventory supply agreement ($14,645 net of tax), $17,959 of goodwill impairment charges ($17,959net of tax), $7,373 of impairment of equity investment ($7,373 net of tax), $9,274 in losses at sites that were closed during the year ($6,533 net of tax), $1,459 gain on sale of investment ($945 net of tax) and favorable income tax items totaling $11,501.(c) Three months ended December 31, 2011 include, as applicable, $8,667 in restructuring costs ($5,961 net of tax), $10,287 in costs associated with the termination of an inventory supply agreement and related inventory write-down ($7,130 net of tax), $12,119 impairment of equity investment ($12,119 net of tax) and favorable income tax items totaling $1,769.(d) Year ended December 31, 2011 includes, as applicable, $24,369 in restructuring costs ($16,067 net of tax), $10,287 in costs associated with the termination of an inventory supply agreement and related inventory write-down ($7,130 net of tax), $12,119 impairment of equity investment ($12,119 net of tax) and favorable income tax items totaling $2,469.Excluding the impa
'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... development and growth strategy expert Jay Warden as Senior Vice President, heading the ... company’s efforts to provide the best solutions to healthcare providers’ needs in ways ...
(Date:7/7/2015)... Dallas, TX (PRWEB) , ... July 07, 2015 , ... Ticket Down is a reputable ... Panama vs. Haiti and the United States vs. Honduras at the Toyota Stadium. ... today, July 7th at Toyota Stadium. The tournament, being held on American soil, will ...
(Date:7/7/2015)... ... ... Greatist today announced the acquisition of Blood, Sweat & ... fun activities to do with friends. , The acquisition of BSC strengthens Greatist’s leadership ... events, e-commerce, and brand partnerships. , “I’ve been a huge fan of Blood, Sweat ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
(Date:7/7/2015)... ... ... Healthpointe is proud to announce the addition of Dr. Pedro S. ... will be evaluating and treating patients with orthopedic complaints, such as lumbar back pain ... Science in Biology from the University of the East, Manila, Dr. Alupay earned his ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
... of Genetic research has indeed unleashed several social and moral ... within themselves.// However, it has also managed to shed new ... recent announcement made by a U.S research team from the ... the understanding of genes which many think; may be ...
... exercise is just as good at beating mild to moderate ... five different exercise programs for people with mild to moderate ... among those taking part in aerobic exercises like walking on ... study involved 80 people with mild to moderate depression who ...
... Heart disease is at least six-times more likely to kill ... researchers based on findings of a recent study . ... high risk because of diabetes or multiple risk factors were ... how doctors managed their cholesterol levels. ,Researchers found only ...
... girls are affected more than boys. Researchers say sex-linked // ... diagnosed with type 2 diabetes. ,Researchers are in the ... children are insulin-resistant and why. The study included 307 healthy ... until they are 16 years old. Researchers are keeping track ...
... Researchers say adding radiation therapy to a treatment regimen ... leads to better survival outcomes among women with high-risk ... ,Ina study done between 1979 and 1986, 318 ... no radiation at all. In a 20-year follow-up, researchers ...
... heart disease risk factors may reduce the risk of ... study // which shows that cardiovascular risk factors in ... in old age. ,Risk factors for cardiovascular ... of these cardiovascular risk factors identified at midlife (ages ...
Cached Medicine News:
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: